The clinical utility of gene expression assays in breast cancer patients with 0-3 involved lymph nodes

Mali Barbi; Della Makower; Joseph A Sparano

doi:10.1177/17588359211038467

The clinical utility of gene expression assays in breast cancer patients with 0-3 involved lymph nodes

Ther Adv Med Oncol. 2021 Aug 14:13:17588359211038467. doi: 10.1177/17588359211038467. eCollection 2021.

Authors

Mali Barbi¹, Della Makower², Joseph A Sparano³

Affiliations

¹ Montefiore Einstein Center for Cancer Care, Bronx, NY, USA.
² Department of Oncology, Montefiore Medical Center, 1695 Eastchester Rd, Bronx, NY 10461, USA.
³ Division of Hematology/Oncology, Mt. Sinai School of Medicine, New York, NY, USA.

Abstract

Multigene expression assays are prognostic for recurrence in hormone-receptor positive 2 (HER-2) negative breast cancer, and, in some cases, predictive of benefit from chemotherapy or extended endocrine therapy. The results of these assays may be used to guide treatment recommendations for early HER-2 negative breast cancer. We review the results of trials establishing the clinical utility of several commercially available gene expression assays.

Keywords: breast cancer; chemotherapy; gene expression profiling; hormone receptor-positive breast cancer; hormone therapy.

Publication types

Review